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Screening for cell-surface proteins up-regulated under stress conditions may lead to 
the identification of new therapeutic targets. To search for genes whose expression was 
enhanced by treatment with oligomycin, a mitochondrial-F0F1 ATP synthase inhibitor, 
signal sequence trapping was performed in H9C2 rat cardiac myoblasts. One of the genes 
identified was that for neural cell adhesion molecule (NCAM, CD56), a major regulator of 
development, cell survival, migration, and neurite outgrowth in the nervous system. 
Immunohistochemical analyses in a mouse myocardial infarction model revealed that 
NCAM was strongly expressed in residual cardiac myocytes in the infarcted region. 
Increased expression of NCAM was also found during the remodeling period in a rat model 
of hypertension-induced heart failure. Lentivirus-mediated knockdown of NCAM 
decreased the cell growth and survival following oligomycin treatment in H9C2 cells. In 
primary rat neonatal cardiac myocytes, NCAM was also found to be up-regulated and 
played a protective role following oligomycin treatment. Analyses of downstream signaling 
revealed that knockdown of NCAM significantly decreased the basal AKT phosphorylation 
level. In contrast, NCAM-mimetic peptide P2d activated AKT and significantly reduced 
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oligomycin-induced cardiomyocyte death, which was abolished by treatment with the PI3K 
inhibitor LY-294002 as well as overexpression of the dominant-negative AKT mutant. 
These findings demonstrate that NCAM is a cardioprotective factor up-regulated under 




It is generally regarded that following chronic pressure and volume overload and after 
regional myocardial infarction (MI), the heart gradually develops a diminished capacity to 
generate adenosine triphosphate (ATP) required for the heart to maintain cardiac output at 
an adequate level [1-3]. Consistent with this, reductions in tissue content and the activity of 
complexes I-IV of the mitochondrial respiratory chain have been reported in animal models 
of cardiac failure and in end-stage human failing hearts [4-6].   
A growing body of evidence shows that as a response to various pathological 
conditions, the heart produces membrane and/or secretes factors to maintain its 
performance in heart failure [7-10]. In order to find membrane and/or secretes factors 
up-regulated under metabolic stress, a signal sequence trapping (SST) method, a general 
strategy for cloning secreted proteins and type I membrane proteins, was applied using a 
U3Ceo vector in H9C2 rat cardiac myoblasts in combination with a functional cloning 
method with oligomycin, a mitochondrial-F0F1 ATP synthase inhibitor [11].   
One of the genes identified was that for neural cell adhesion molecule (NCAM, CD56), 
a major regulator of development, cell survival, migration, and neurite outgrowth in the 
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nervous system [12, 13]. Homophilic and heterophilic NCAM binding result in the 
activation of a number of signaling cascades, which in turn result in context-dependent 
biological responses in neuronal cells [14-16]. However, the biological function of NCAM 
in cardiac myocytes remains unknown. 
Here, it is reported that (1) NCAM is a type I membrane protein identified by SST in 
H9C2 cardiomyoblasts induced by oligomycin treatment, (2) NCAM was up-regulated in a 
mouse MI model and during the remodeling period of hypertrophy to heart failure in a Dahl 
salt-sensitive rat model, (3) endogenous NCAM contributed to AKT activity and protected 
cardiac myocytes from cell death induced by oligomycin-induced metabolic stress, and (4) 
treatment with NCAM mimetic peptide P2d activated AKT and improved the 
cardiomyocyte survival rate against metabolic stress.  
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2. Materials and methods 
 
2.1. Reagents 
Oligomycin, SB202190, SP600125, and LY294004 were purchased from Calbiochem. 
The P2d and scrambled P2d (scrP2d) peptides were generous gifts from Professor Elisabeth 
Bock (Panum Institute, University of Copenhagen, Copenhagen, Denmark) and 
STEMCELL Technologies Inc.(Vancouver, BC, Canada).  
 
2.2. Cell culture 
The rat myocyte cell line H9C2 was obtained from the American Type Culture 
Collection (Rockville, MD, USA) and maintained in DMEM supplemented with 10% fetal 
bovine serum (FBS). Isolation of primary neonatal rat ventricular cardiomyocytes was 
carried out using an established procedure as described previously [17] and cultured in 
medium containing 10% FBS.  
 
2.3. Plasmid and cell infection 
The U3Ceo retroviral vector was a gift from Harald von Melchner (University of 
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Frankfurt Medical School). Viruses were produced at 32°C, and virus-containing medium 
was collected 24 h post-transfection and filtered through a 0.45 µm filter. H9C2 cells were 
plated in six-well plates at a density of 5×105 cells/well. One round of retroviral infection 
was performed by replacing the medium with 2 mL of U3Ceo virus (containing 8 µg/mL of 
Polybrene, Sigma-Aldrich), followed by centrifugation of the six-well plates at 1220×g for 
30 min at 32°C. Stably transfected clones were selected in normal growth medium with the 
addition of G-418 (1 mg/mL).  
The oligonucleotide used for small interfering RNA (siRNA) of NCAM was 
NCAM-siRNA: sense 5’ GGCAGGAGATGCCAAAGAT-3’. The siRNA construct was 
made using a pSINsi-mU6 vector (Takara Bio., Inc.). siRNA and the dominant negative 
form of rat AKT1 (AKT-AA: T308A/S473A) [18] was introduced into the lentivirus vector 
plasmid pLenti6/V5-D-TOPO vector (Invitrogen) and transduced into cardiac myocytes as 
was done for retroviral infection. 
 
2.4. Flow Cytometry 
After the indicated treatments, the cells were washed quickly and suspended in 50 μL 
PBS and incubated for 30 min at 4°C with 5 μL of FITC conjugated CD2 (Leu-5b). Cells 
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were washed 3 times with PBS, suspended in 500 μL PBS, and analyzed using a FACS 
Aria (BD Biosciences) with FITC-specific settings.  
 
2.5. 5’-RACE 
5’-RACE was performed with 5 µg of total RNA using a 5’RACE System for Rapid 
amplification of cDNA Ends, version 2.0 (Invitrogen), in accordance with the 
manufacturer’s instructions. CD2 specific primers were 
5’-CAAGTTGATGTCCTGACCCAAG-3’ and 
5’-GGTTTCCAAGGCATTCGTAATCTC-3’. The amplification of tailed cDNA was 
performed using 35 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 2 min.  
 
2.6. Western blotting 
For NCAM assays, a polyclonal rabbit anti-rat NCAM antibody (diluted 1:5000; a 
generous gift from Professor Elisabeth Bock,) was used as the primary antibody, and an 
anti-rabbit Ig peroxidase conjugate (whole molecule conjugate; diluted 1:2000; Sigma) as 
the secondary antibody. An anti-β-actin antibody (diluted 1:3000; Sigma) was used as a 
loading control. Anti-phosphospecific p38 (diluted 1:250), anti-phosphospecific AKT 
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(Ser473) (diluted 1:1000), anti-total AKT (diluted 1:500) and anti-phosphospecific JNK 
antibodies (diluted 1:500) were obtained from Cell Signaling. Anti-phosphospecific ERK 
1/2 (diluted 1:500), anti-total ERK 1/2 (diluted 1:500), anti-total p38 (diluted 1:200) and 
anti-total JNK (diluted 1:500) was obtained from Santa cruz.  
 
2.7. Real-time PCR 
For real-time PCR, the reaction was performed using a SYBR Green PCR master mix 
(Applied Biosystems), and the products were analyzed using a thermal cycler (ABI Prism 
7900HT sequence detection system). The levels of GAPDH transcripts were used to 
normalize cDNA levels.  
Gene-specific primers were as follows:  
rat NCAM sense, 5’ AATCAGCGTTGGAGAGTCCA-3’,  
antisense, 5’ CGTCTTCAGCGGTGACCA-3’,  
mouse NCAM sense, 5’ ACAGAAACCCGTGGAGATG-3’,  
antisense, 5’ GTCTCTGTGGCTCTCGTTCC-3’  
(these primers recognized all forms of NCAM splicing variants) ;  
rat ANF sense, 5’ CGTGCCCCGACCCACGCCAGCATGGGCTCC-3’,  
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antisense, 5’ GGCTCCGAGGGCCAGCGAGCAGAGCCCTCA-3’; and 
GAPDH sense, 5’ TTGCCATCAACGACCCCTTC-3’, 
antisense, 5’ TTGTCATGGATGACCTTGGC-3’. 
 
2.8. ATP measurement 
Intracellular ATP concentration was measured using an ATP bioluminescence assay kit 
(TOYO ink) in accordance with the manufacturer’s protocol and the data was normalized 
for total cell protein. 
 
2.9. Cell proliferation assay and BrdU uptake 
H9C2 cells transfected with either control-siRNA or with NCAM-siRNA, were plated at 
1.2×104/mL into 10 cm dishes and cultured in DMEM containing 10% FBS. The number of 
H9C2 cells was counted using a cell counter (COULTER particle counter, GMI). BrdU 
uptake by H9C2 cells was quantified using a BrdU Labeling and Detection Kit III as 
described by the manufacturer (Roche Diagnostics). 
 
2.10. MTT assay  
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Quantitative determination of viable cells was performed using an MTT assay. Briefly, 
the cells were labeled with MTT (Thiazolyl Blue Tetrazolium Bromide, Sigma) at a final 
concentration of 0.5 mg/mL for at least 4 h at 37°C. Viability was then evaluated by 
measuring the absorbance at 595 nm using an Elx800 Microplate Reader (BIO-TEK 
Instruments Inc.).  
 
2.11. Two-color fluorescence cell viability assay 
Simultaneous determination of live and dead cells was performed using a LIVE/DEAD 
Viability/Cytotoxicity Assay Kit (Invitrogen). Briefly, after the indicated treatments, cells 
were labeled with calcein AM (2 µM) and ethidium homodimer-1 (4 µM) probes, which 
are specific for intracellular esterase activity and membrane integrity, respectively. The 
number of live cells (labeled green) and dead cells (labeled red) was counted in 15 random 
microscopic fields (×100) per experiment using a fluorescence microscope. The ratio of 
live cells (green/ green+ red) was calculated and used to determine the cell viability (%).  
 
2.12. Animal Tissue 
The investigation conformed with the Guide for the Care and Use of Laboratory Animals 
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published by the National Institutes of Health (NIH Publication No. 85-23, Revised 1996), 
and was approved by the Institutional Animal Research Committee of Kyoto University. In 
experiments using an MI model mouse, C57/BL6 mice were anesthetized with 0.5% 
pentobarbital (Dainippon Sumitomo Pharma), and open-chest coronary artery ligation was 
performed. MI was induced by ligating the left anterior descending coronary artery. In 
sham-operated mice, open-chest surgery was performed without coronary artery ligation. 
At the indicated number of days after surgery (n=3 per group), hearts were isolated for 
immunohistochemical and real-time PCR analyses. In experiments using Dahl salt-sensitive 
(DS) rats, male DS rats were fed an 8% NaCl (high-salt) diet after the age of 6 weeks. The 
animals were sacrificed at the LVH (11 weeks) and CHF (17 weeks) stages. DS rats that 




Immunohistochemical staining was performed using a conventional (ABC) method. 
Briefly, incubation and washing procedures were carried out at room temperature. After 
deparaffinization and antigen retrieval, endogeneous peroxidase activity was blocked using 
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0.3% H2O2 in methylalcohol for 30 min. The glass slides were washed in PBS (6 times, 5 
min each) and mounted with 1% normal serum in PBS for 30 min. Subsequently 
anti-NCAM rabbit polyclonal antibody H-300 (Santa Cruz) diluted to 1:100 in PBS was 
applied overnight at 4°C. The slides were incubated with biotinylated anti-rabbit serum 
(second antibody) diluted to 1:300 in PBS for 40 min, followed by washes in PBS (6 times, 
5 min each). Avidin-biotin-peroxidase complex (ABC) (ABC-Elite, Vector Laboratories) at 
a dilution of 1:100 in PBS was applied for 50 min. After washing in PBS (6 times, 5 min 




Data are presented as means±SEM. Statistical significance (P<0.05) was determined 
between groups using an ANOVA followed by Tukey's Multiple Comparison Test for 




3.1. NCAM was identified to be up-regulated under metabolic stress in H9C2 cells  
 Oligomycin, a specific blocker of mitochondrial-F0F1 ATP synthase, was used to induce 
metabolic stress. Treatment of H9C2 cells with 20 µM oligomycin for 48 h significantly 
decreased the cellular ATP concentration (Fig. 1A).  
In order to identify the genes of secreted proteins and type I membrane proteins 
up-regulated under metabolic stress, SST method in combination with a functional 
screening was performed, using the U3Ceo vector [11] in H9C2 rat cardiac myoblasts. An 
overview of the experimental procedure is indicated in Fig. 1B. In the U3Ceo vector, 
human CD2 cell antigen/neomycin-phosphotransferase fusion gene (Ceo) is inserted into 
the 3’-long terminal repeat (LTR). After U3Ceo retroviral infection, proviral integrations 
into the introns of expressed genes in the target cells result in splicing of exons upstream to 
Ceo, leading to cell-provirus fusion transcription. If these exons possess a signal sequence, 
it enables fusion protein transport to the cell membrane and makes the cells CD2 positive 
and G418 resistant. After U3Ceo retroviral infection, CD2 expression was estimated by 
flow cytometry and CD2-negative cells were collected and expanded for the next 
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experiment (Fig. 1B, 1st sorting, red). After oligomycin treatment, a small portion of cells 
treated with oligomycin became CD2 positive (Fig. 1B, 2nd sorting, blue). These 
CD2-positive cells were collected and expanded in complete growth medium to form single 
clones. Samples from each clone were collected and analyzed to determine the identity of 
the inserted genes. The fused mRNA of U3Ceo and an endogenous gene in 
oligomycin-treated CD2-positive cells was amplified by 5’ rapid amplification of cDNA 
ends (5’-RACE). In one of the clones obtained, the junctional sequence of the fused cDNA 
revealed that viral insertion occurred at the 3' end of exon 1 of the NCAM gene (Fig. 1C). 
To ensure that CD2 expression was truly regulated by oligomycin treatment, the pattern 
of CD2 expression was examined in this clone. Flow cytometry analysis revealed that 
treatment with oligomycin for 48 h induced cell surface CD2 expression (Fig. 1D). This 
effect was concentration- and time-dependent (Fig. 1E). In this clone, endogenous NCAM 
was truncated by the insertion of U3Ceo, and the fusion protein might be expressed in a 
different way from intact NCAM. Thus, the level of endogenous NCAM expression was 
analyzed in H9C2 cells. Real-time PCR analysis showed that significant up-regulation of 
NCAM mRNA expression was observed at 48 h after treatment with oligomycin (Fig. 1F). 
Western blotting revealed that H9C2 cells expressed NCAM 120 and 140 with NCAM 140 
 16 
predominating under basal conditions. Oligomycin treatment up-regulated NCAM 140, 
while the expression of NCAM 120 was unchanged. (Fig. 1G).  
 
3.2. Histological examination in a mouse model of myocardial infarction 
 Next, the expression pattern of NCAM in the hearts was analyzed. Myocardial ischemia is 
a typical model of metabolic stress in the diseased heart. Thus, the expression of NCAM in 
a mouse model of MI was examined. The expression levels of NCAM in sham-operated 
(n=3) and MI mice (n=4) were determined by real time PCR analysis. Apex in an MI 
mouse indicates an infarcted area and septum in an MI mouse indicates a non-infacted area. 
Significant NCAM up-regulation was observed in infracted areas at 7 days after surgery 
(Fig. 2A). By immunohistochemistry, staining of NCAM in control mice was only 
observed in the intercalated discs (Fig. 2B and C). However, in the MI model, strong 
staining was observed in the myocardium adjacent to the infarcted area (Fig. 2D and E); 
whereas, staining was restricted to the intercalated disks in remote areas (Fig. 2F). Even in 
the chronic phase at 12 months after surgery, strong NCAM staining was still detected in 
residual myocytes in the scared fibrotic area (Fig. 2G).  
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3.3. Histological examination in a rat model of heart failure 
Load-induced hypertrophy triggers metabolic stress, leading to pathological remodeling 
and heart failure [1-3]. To examine the change in NCAM expression pattern during this 
process, a rat model of hypertension-induced heart failure was analyzed. In Dahl 
salt-sensitive (DS) rats on a high-salt diet, systemic hypertension caused compensated 
concentric left ventricular hypertrophy (LVH stage) at the age of 11 weeks, followed by 
marked LV dilatation and global hypokinesis at 17 weeks (CHF stage) [19-21]. Fig. 3A 
indicates that the ANF expression level increased in the LV of DS rats at the LVH and CHF 
stages, as determined by real-time PCR analyses, while the ANF expression levels were 
unchanged in the LV of control rats, which were fed on a low salt (0.5% NaCl) diet.   
Immunohistochemical staining of NCAM in DS rats was performed. Similar to the 
mouse model, the staining in the control rats at the age of 11 weeks was very weak and 
restricted to the intercalated discs (Fig. 3B and Fig. 3C). However, at the LVH stage of DS 
rats fed on a high-salt diet, a strong and heterogeneous expression pattern of NCAM 
staining was observed. As shown in Fig. 3D-3H, NCAM was mainly expressed in the endo- 
and subendo-cardium facing the ventricular cavity, whereas its expression was very weak 
in the subepicardial area. To further analyze the distribution pattern of NCAM staining, 
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Masson's Trichrome staining was performed, and it was revealed that the myocardium 
surrounding the fibrotic area (arrows in Fig. 3I) had intense staining of NCAM (arrowheads 
in Fig. 3J. Fig. 3I and J are the sequential section) at the LVH stage. 
At the CHF stage, strong NCAM staining was observed throughout the myocardium (Fig. 
3K and 3L). Fig. 3M is the staining of NCAM in control rats at the age of 17 weeks. 
The NCAM levels in the LV of DS rats at LVH and CHF periods were quantified by 
real-time PCR analyses and western blotting analysis (Fig. 3N and O). Consistent with the 
results of immunohistochemical analyses, both mRNA and protein of NCAM expression 
levels were enhanced in the LVH stage, and significant and strong expression was observed 
in CHF stage. 
 
3.4. Knockdown of NCAM reduced proliferation of H9C2 cells and reduced the survival 
rate following oligomycin treatment  
To investigate the function of NCAM in cardiac myocytes, an siRNA construct directed 
against NCAM was generated and introduced by lentivirus, leading to an effective decrease 
in the expression of both NCAM120 and 140 in H9C2 cells (Fig. 4A). Interestingly, 
transfection of H9C2 cells with NCAM-siRNA was found to decrease their proliferation  
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rate (Fig. 4B). In consistent with this, the uptake of 5-bromo-2’-deoxyuridine (BrdU) was 
also decreased by the knockdown of NCAM (Fig. 4C), indicating that endogenous NCAM 
played a significant role in H9C2 cell proliferation.  
 Next, H9C2 cells transfected with control-siRNA or NCAM-siRNA vector were treated 
with oligomycin for 48 h, and the role of NCAM in cell survival under metabolic stress was 
evaluated. As shown in Fig. 4D, oligomycin treatment induced severe cell shrinkage when 
NCAM was knocked down. Consistent with the reduction in the proliferation rate, the MTT 
level was significantly reduced in NCAM-knocked down H9C2 cells under basal 
conditions and decreased further after oligomycin treatment (Fig. 4E).  
To further confirm that NCAM protects against oligomycin-induced metabolic stress, 
simultaneous determination of live and dead cells was performed. Under basal conditions, 
although the number of viable cells was decreased when NCAM was knocked-down (Fig. 
4G main graph, siCTRL oligomycin- vs. siNCAM oligomycin-), this was mainly due to a 
decrease in the proliferation rate and not to cell death, since no significant increase in dead 
cells was observed in this group (Fig. 4G main graph, siCTRL oligomycin- vs. siNCAM 
oligomycin-). Indeed, when cell viability (live cells (green)/total cells (green+red)) was 
determined in each group, more than 99% of H9C2 cells were found to be viable in both 
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control and NCAM-knocked-down H9C2 cells (Fig. 4G inset, siCTRL oligomycin- and 
siNCAM oligomycin-). Although the number of viable cells was decreased by oligomycin 
treatment in control-siRNA transfected H9C2 cells (Fig. 4G main graph, siCTRL 
oligomycin- vs. siCTRL oligomycin+), this was mainly due to a decrease in cell growth 
and not to enhanced cell death, since nearly 90% of cells were shown to be alive (Fig. 4G 
inset, siCTRL oligomycin+). However, treatment with oligomycin in 
NCAM-knocked-down H9C2 cells resulted in increased cell death, which in turn led to less 
than 50% cell viability (Fig. 4G main graph and inset, siNCAM oligomycin+).  
These results suggest that endogenous NCAM plays a significant role in protecting against 
metabolic stress as well as in cell proliferation in H9C2 cells. 
 
3.5. Expression and protective function of NCAM in primary rat neonatal cardiac myocytes  
 The expression and function of NCAM during metabolic stress was also analyzed in 
primary rat neonatal cardiac myocytes. Because primary rat neonatal cardiac myocytes 
were more susceptible to metabolic stress, treatment with low concentration of 0.1 µM 
oligomycin for 48h significantly reduced the intracellular ATP concentration (Fig. 5A). 
Treatment with oligomycin rapidly activated stress responsive MAPK p38, while JNK was 
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not activated (Fig. 5B). A significant up-regulation of NCAM mRNA was observed at 48 h 
after treatment with oligomycin (Fig. 5C). Western blotting analysis showed that, similar to 
H9C2 cells, primary rat neonatal cardiac myocytes expressed NCAM 120 and 140, and that 
both variants were up-regulated by oligomycin treatment (Fig. 5D).  
To determine whether the activation of MAPK might be responsible for the up-regulation 
of NCAM under metabolic stress, cells were treated with the p38 inhibitor SB202190 or the 
JNK inhibitor SP600125 and the expression of NCAM was analyzed. Under the basal 
conditions, neither JNK inhibitor nor the p38 inhibitor affected the mRNA and protein 
expression levels of NCAM (Fig. 5E). However, under oligomycin treatment, the p38 
inhibitor SB202190 completely abolished the increases in the mRNA and protein 
expression levels of NCAM, while the JNK inhibitor SP600125 had no effect (Fig. 5F). 
Thus, up-regulation of NCAM under metabolic stress was revealed to be mediated by the 
activation of p38.  
To determine the protective role of endogenous NCAM against oligomycin-induced 
metabolic stress, primary rat cardiac myocytes transfected with control-siRNA or 
NCAM-siRNA vector were treated with oligomycin and the survival rate was evaluated by 
MTT assay and a two-color fluorescence cell viability assay. As shown in Fig. 5G and Fig. 
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5H, both assays confirmed that knockdown of NCAM resulted in a significant reduction in 
survival rates following oligomycin treatment in primary rat cardiac myocytes.  
These results suggested that expression of NCAM were enhanced and played a protective 
role in oligomycin-induced metabolic stress in primary rat neonatal cardiac myocytes. 
 
3.6. Signal transduction and protective role of NCAM mimetic peptide P2d  
Next, the downstream signaling of NCAM was evaluated in primary rat cardiac 
myocytes. AKT and ERK have been demonstrated to be the major downstream pathway 
elements in NCAM-induced signaling, and activation of these signaling pathways via 
NCAM has been reported to lead to cell survival effects in neuronal cells [14-16]. 
Therefore, the activation level of AKT and ERK was analyzed. As shown in Fig. 6A and 
6B, it was found that the level of phosphorylated AKT was significantly reduced when 
NCAM was knocked down, whereas phosphorylated ERK levels remained unchanged, 
suggesting that NCAM was involved in AKT-mediated signaling. To further explore the 
NCAM-mediated signaling in cardiac myocytes, the effect of stimulation of NCAM was 
also analyzed using NCAM mimetic peptide P2d. P2d was synthesized as a dendrimer 
composed of four monomers corresponding to a 12-amino-acid sequence (GRILARGEIN 
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FK) in the second immunoglobulin (Ig)-like module of NCAM [22]. As shown in Fig. 6B, 
treatment with P2d at concentrations of 20µg/ml and 50µg/ml for 24 h activated AKT, 
whereas treatment with low concentration of P2d (5µg/ml) or with its scrambled form 
scrP2d (NLFEKGRRAIGI) (5-50µg/m) did not. Neither peptide activated ERK. Moreover, 
P2d protected cardiac myocytes from cell shrinkage during oligomycin treatment (Fig. 6C). 
An MTT assay was performed following treatment with 0.1µM oligomycin for 48 h in the 
presence of scrP2d or P2d at the indicated concentrations, and the results showed that P2d, 
but not scrP2d, reduced the rate of cell death at concentrations of 20µg/ml and 50µg/ml 
(Fig. 6D). To determine whether activation of AKT mediated the protective role of P2d, 
the effect of LY-294002 (10 µM) on cell survival was analyzed. It was found that 
LY-294002 completely abolished the cell survival effect of P2d (Fig. 6E). Furthermore, 
overexpression of the dominant negative form of AKT also eliminated the protective effect 
of P2d against oligomycin treatment (Fig. 6F). Taken together, these results indicated that 




It is known that the failing heart expresses various adaptation proteins that work to 
protect the heart from injury [7-10]. Such factors can be used as biomarkers or therapeutic 
targets for heart failure. Among these, membrane proteins are easily accessible to 
exogenous drugs and are thus the preferred targets for drug development. The failing heart 
is characterized by alterations in energy metabolism, including mitochondrial dysfunction 
[1-6]. Oligomycin inhibits mitochondrial function by blocking F0F1 ATP synthase, leading 
to reduced ATP content. After the removal of oligomycin-containing medium and 
replacement with complete growth medium, the residual cells could be grown for further 
analyses. Thus, functional screening in combination with an SST method, which is a 
general strategy for cloning secreted proteins and type I membrane proteins, was set up to 
search for the genes that encode membrane proteins and are up-regulated by oligomycin 
treatment.  
Through this approach, several genes encoding secreted and membrane proteins were 
identified. One of these genes was plasminogen activator inhibitor-1 (PAI-1) known to be 
up-regulated under the hypoxic condition [23], which supported the feasibility and 
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usefulness of our functional screening method.  
In the present study, NCAM was identified as being up-regulated by oligomycin 
treatment in cardiac myocytes. It was also observed that NCAM was up-regulated in a 
mouse MI model. This was similar to the previous reports demonstrating the up-regulation 
of NCAM in ischemic cardiomyopathy [24]. NCAM was also found to be extensively 
up-regulated during the remodeling period of hypertrophy to heart failure in a Dahl 
salt-sensitive rat model. In particular, the expression pattern of NCAM in hypertensive 
hearts was impressive; NCAM was not expressed on the subepicardial side but was 
expressed strongly in the subendocardium area. These lesions are known to suffer readily 
from relative ischemia and metabolic stress and tend to develop fibrotic changes [25]. 
Indeed, strong expression of NCAM was found surrounding the fibrotic area.  
Previous reports demonstrated that myocardial NCAM immunostaining was displayed 
from embryonic day E12 in the heart and increased up until postnatal day 1 and then 
declined rapidly thereafter [26]. Similarly, the present study found that immunostaining of 
NCAM was very scarce in normal adult hearts and restricted to the intercalated disks. 
Therefore, re-expression of NCAM under metabolic stress may be regarded as the 
reactivation of the fetal gene program, observed in the hemodynamically or metabolically 
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stressed heart, such as ANF re-expression, myosin heavy chain gene isoform switches, and 
GLUT isoform switches [27] and may be a sensitive marker for these conditions. 
To investigate the pathways associated with NCAM induction in response to 
metabolic stress, the activation of stress-regulated MAP kinases was examined. It was 
found that p38 was rapidly activated by oligomycin treatment and blockage of p38 
abolished the induction of NCAM expression. This is the same as with another neural cell 
adhesion molecule, contactin1, which was also reported to be induced by the p38 
MAPK-dependent pathway [28]. p38 was reported to be involved in pathophysiology of 
ischemic and hypertensive heart disease [29, 30]. Thus, it is likely that expression of 
NCAM in MI and hypertensive hearts is also dependent on p38 activation. 
The function of NCAM has been studied intensively in neuronal cells and has been 
shown to be involved in various biological process including cell migration, survival, and 
neuronal development. NCAM also has been shown to induce the activation of ERK and is 
anti-apoptotic via activation of the PI3K-AKT pathway in neurons [14, 16, 31]. In the 
present experiments with cardiac myocytes, it was shown that NCAM played a significant 
role in cell growth and survival under metabolic stress. Moreover, while basal ERK 
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activation did not change, NCAM-siRNA reduced AKT phosphorylation levels, suggesting 
that this pathway might be involved with the protective function of NCAM. 
To further explore this signaling pathway, the effect of stimulation of NCAM was 
examined. Recently, by means of combinatorial chemistry and based on the unraveling of 
the structure of NCAM, a number of peptides that mimic NCAM homophilic binding have 
been developed [32, 33]. The P2 peptide, GRILARGEINFK, is a conserved sequence 
fragment of NCAM derived from the second Ig module, which represents the natural 
binding partner of the first Ig module of NCAM. The dendrimeric form of P2 (P2d) has 
been shown to bind NCAM IgI with an apparent Kd of 4.7 µM [22]. Thus, P2d has a 
mimetic function of NCAM homophilic binding. The effects of P2d have been examined in 
primary cerebellar and dopaminergic neurons, and it promotes neutrite outgrowth and 
protects against neuronal cell death [31, 34]. Here, it was demonstrated that P2d peptide 
also had a cardioprotective effect against metabolic stress via the PI3K-AKT pathway.   
There are several possible mechanisms by which activation of NCAM can lead to 
activation of AKT. One possible mechanism involves FAK which is phosphorylated upon 
binding to the activated NCAM-Fyn complex [35]. PI3K has been shown to bind via the 
SH-2 domain of the p85 subunit to phosphorylated FAK, and this binding leads to 
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activation of PI3K and AKT [36]. Since activation of PI3K and AKT by phosphorylated 
FAK has been shown to protect cardiac myocytes from cell death under glucose deprivation, 
this pathway may be involved in NCAM mediated signaling and protection [37]. Another 
possible mechanism involves the FGFR which is activated upon homophilic 
NCAM-binding [38]. The FGFR has been shown to induce PI3K and AKT activation 
through recruitment of multiple docking proteins [39]. Thus, NCAM mediated activation of 
FGFR may induce the protective effect. 
In conclusion, NCAM is specifically up-regulated in stressed cardiomyocytes, and 
augmentation of this signal improved cardiomyocyte survival through PI3K-AKT 
activation. Enhancement of NCAM-signaling by synthetic peptides may provide a novel 
strategy for heart failure therapy.  
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Figure legend 
Fig. 1. Overview of the experimental procedure. (A) Measurement of cellular ATP 
concentration. H9C2 cells were treated with oligomycin (20 µM) for 48h. ATP 
concentration of untreated cells were set as 100%. Values are means±SEM, n=3. * P<0.01 
n=3. (B) Overview of the experimental procedure. After U3Ceo retroviral infection, 
proviral integration into the introns of expressed genes results in splicing of upstream exons 
to the CD2/Neo gene. G418-resistant cells were treated with an FITC-conjugated 
monoclonal anti-CD2 antibody. CD2 expression was estimated by flow cytometry and 
CD2-negative cells were collected (1st sorting, Figure1-B, red) and expanded for 
oligomycin treatment. After treatment with oligomycin (20 µM) for 48h, the cells were 
collected again and analyzed for CD2 expression. In this step, CD2-positive cells were 
sorted and expanded to form single clones. (2nd sorting, Figure1-B, blue ). Samples from 
each clone were collected and analyzed for identification of the inserted genes by 5’ rapid 
amplification of cDNA ends (5’-RACE, see Materials and Methods). (C) The junctional 
sequence of the fused cDNA in one of the clones obtained. SS; Signal sequence, SD; 
splicing donor, SA; splicing acceptor. (D) Cell surface CD2 levels of an untreated clone left 
(control) or treated with oligomycin (20 µM) for 48 h. The FITC level analyzed in cells 
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without FITC-conjugated monoclonal anti-CD2 antibody was set as a negative control. (E) 
The FITC level of cells treated with various concentrations and for various time periods. 
Values are means±SEM from at least three experiments. *P<0.01 vs control, **P<0.001 vs 
control. (F) and (G) Expression levels of NCAM mRNA (F) and protein (G) in H9C2 cells 
treated with oligomycin (20 µM) were examined by real-time PCR and western blotting 
analyses. β-actin is shown as a loading control. Values are means±SEM from at least three 
experiments. *P<0.01 vs. control;  
 
Fig. 2. NCAM is up-regulated in mouse MI model. (A) Expression levels of NCAM in 
sham-operated (n=3) and MI mice (n=4) were determined by real-time PCR analyses. Apex 
area in MI mouse indicates infarcted area and septal area in MI mouse indicates 
non-infacted area. Values are means±SEM, *P<0.01, **P<0.001. (B)-(G)  
Immunohistochemical staining of NCAM in control and infarcted mice. (B) and (C) 
sham-operated mouse. (D)-(F) MI-operated mouse (day7). (E) infarcted area. (F) remote 
area. (G) infarct area of MI-operated mouse (12 months).   
 
Fig. 3. NCAM is up-regulated in a rat model of hypertension-induced heart failure. (A) 
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ANF expression levels in the LV of DS rats at LVH and CHF stages were determined by 
real-time PCR analyses. Values represent arbitrary units (the 11W control values were set 
at 1.0). Values are means ± SEM, *P<0.01, **P<0.001. (B)-(M) Immunohistochemical 
staining of NCAM in DS rats. (B) and (C) 11 weeks LS (control). (D)-(J) 11 weeks HS 
(LVH). (H) Cross-section of LV in LVH rat. (I) and (J) Sequential section of LV in LVH 
rat. (I) Masson Trichrome stain. (J) NCAM staining. (K) and (L) 17 weeks HS (CHF). (M) 
17 weeks LS (control). (N) NCAM mRNA level in the LV of DS rats at LVH and CHF 
periods were determined by real time PCR analyses. 11 weeks control, 11 weeks LVH, and 
17 weeks control; n=6, 17 weeks CHF; n=7. Values represent arbitrary units (the 11W 
control values were set at 1.0). Values are means ± SEM, *P<0.001.    
(O) Western blotting analyses of NCAM in the LV of DS rats in the LVH and CHF periods. 
GAPDH is shown as a loading control. 
 
Fig. 4. Knockdown of NCAM reduced the survival rate after oligomycin treatment in H9C2 
cells. (A) Effect of knockdown of NCAM with NCAM-siRNA in H9C2 cells. β-actin is 
shown as a loading control. (B) Effect of knockdown of NCAM on the proliferation rate of 
H9C2 cells. Seventy-two hours after transfection with control-siRNA or NCAM-siRNA, 
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H9C2 cells were plated as 1.2×104/mL and cell proliferation was assessed. Values are 
means ± SEM , *P<0.05 relative to siCTRL. n=3 (C) Knockdown of NCAM decreased the 
BrdU uptake in H9C2. Values are means ± SEM *P<0.0001 from 3 independent 
experiments in 5-6 wells. (D) Phase-contrast image of H9C2 cells transfected with 
control-siRNA or NCAM-siRNA with or without treatment with oligomycin (20 µM) for 
48h. (×200) (E) Viable cells transduced with control-siRNA or NCAM-siRNA with or 
without treatment with oligomycin (20 µM) for 48h was assessed by MTT assay. The MTT 
level of untreated H9C2 cells transduced with control-siRNA was set as 1.0. Values are 
means ± SEM of three independent experiments. *P<0.01, **P<0.001 (F) and (G) Live and 
dead cells in each condition were determined using a two-color fluorescence cell viability 
assay as described in the materials and methods. (F) Representative images of a two-color 
fluorescence cell viability assay (green; viable cells, red; dead cells ×100). (G) The main 
graph shows the actual numbers of live (green) and dead (red) cells per view fields. Live 
cells (green) / total cells (green + red) × 100% in each group was calculated and used for 
cell viability. The result was shown in the inset. Values are means ± SEM, *P<0.001  
 
Fig. 5. NCAM is up-regulated under oligomycin-induced metabolic stress by the p38 
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MAPK dependent pathway and played a protective role in primary neonatal rat cardiac 
myocytes. (A) Measurement of cellular ATP concentration. Primary neonatal rat cardiac 
myocytes were treated with oligomycin (0.1 µM) for 48h. The ATP level of untreated cells 
were set as 100%. Values are means ± SEM, n=3, *P<0.001 (B) Oligomycin (0.1 µM) 
treatment activated p38 but not JNK. (C) The change in endogenous NCAM expression 
level in rat neonatal cardiac myocytes was analyzed by real-time PCR. Values are means ± 
SEM, n=3, *P<0.05 (D) Western blotting analyses of NCAM with or without oligomycin 
(0.1 µM) treatment for 48h. β-actin is shown as a loading control. The lower graph shows 
densitometry analyses. Values are means ± SEM, n=3, *P<0.001. (E) and (F) Effect of P38 
inhibitor (SB202190, 10 µM) and JNK inhibitor (SP600125, 10 µM) on NCAM expression 
under the basal conditions (E) and oligomycin treatment (F) examined by real-time PCR 
and western blotting analyses. SB, SB202190; SP, SP600125; Values are means ± SEM, 
n=3, *P<0.01 vs control. (G) Viable cells transduced with control-siRNA or NCAM-siRNA 
with or without oligomycin (0.1 µM) treatment for 48h were assessed by MTT assay. 
*P<0.001, n=3 (H) Live and dead cells in each condition were determined using a 
two-color fluorescence cell viability assay. Left-hand pictures show representative 
fluorescence microscopic images (×100). Right-hand graph shows the result of cell viability 
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quantified by counting the number of viable (green) and dead (red) cells per experiment. * 
P<0.001  
 
Fig. 6. NCAM is involved in AKT mediated signaling and NCAM mimetic peptide P2d has 
a protective effect against oligomycin-induced metabolic stress via the PI3K-AKT pathway. 
(A) Seventy-two hours after lentivirus infection, phospho-AKT(Ser473), total-AKT, 
phospho-ERK(p42/44), and total-ERK were analyzed by western blotting. The graph shows 
the results of densitometry analysis from three independent experiments. Mean ± SEM, 
*P<0.05 (B) Lysates from cardiac myocytes treated with scrP2d or P2d (5, 20, and 50 
µg/mL) for 24 h were assessed for Akt and ERK activity. β-actin is shown as a loading 
control. (C) Phase-contrast image of cardiac myocytes following oligomycin (0.1 µM) 
treatment for 48h in the presence of vehicle, scrP2d or P2d (20 µg/mL). (D) MTT assay 
was performed following treatment with oligomycin (0.1 µM) for 48 h in the presence of 
scrP2d or P2d as indicated. Mean ± SEM from at least three experiments. **P<0.01 
*P<0.001. (E) Treatment with LY-294002 (10 µM) abolished the cell survival effect of P2d. 
Mean ± SEM, n=6, *P<0.05, **P<0.01. (F) Overexpression of the dominant negative Akt 
eliminated the cell survival effect of P2d. vector; control empty vector, DN-AKT; dominant 
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negative AKT.  Mean ± SEM, n=3, *P<0.001. 
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